Manila Times Business
OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document
2025 Audited financial statements are consistent with Unaudited financial statements previously reported on April 30, 2026The IRIS Financing announced on May 28, 2026, was added as a subsequent eventConfirmed cash runway until the end of December 2026 after the IRIS FinancingNANTES, France, June 3, 2026 - 8:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the "Company"), today reported its full year 2025 audited consolidated financial results, as approved by the Board of Di
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Israel, Lebanon agree to conditional ceasefire
2h ago
Quantinuum Announces Pricing of Upsized Initial Public Offering
2h ago
Origin Energy and Landis+Gyr bring large-scale smart gas technology to Australian homes and businesses
2h ago
Compal and Datasection Advance AI Infrastructure for the Production Era
2h ago